JapanStake
Pharmaceutical · Fiscal year end Mar 31

J-Pharma Co.,Ltd.

520A

ジェイファーマ株式会社

FIGI BBG00Q40P3Y6520A.T520A JPCorp. no. 6011101043476

Financials

Japan GAAP · non-consolidated · fiscal year to 2026-03-31
Revenue
—
Net income
−¥2.5bn
ROE
—
Equity ratio
85.4%
Dividend / share
—
Employees
16
Net income · ¥bn
FY2022: −¥1.1bn -1.08 FY2022FY2023: −¥1.1bn -1.1 FY2023FY2024: −¥1.7bn -1.65 FY2024FY2025: −¥1.5bn -1.5 FY2025FY2026: −¥2.5bn -2.47 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31—−¥2,466m¥4,761m¥4,378m—¥-195.08−¥2,249m
2025-03-31—−¥1,499m¥2,857m¥2,378m—¥-184.05−¥1,695m
2024-03-31—−¥1,652m¥1,207m¥950m—¥-263.57−¥1,411m
2023-03-31—−¥1,098m¥1,752m¥1,408m—¥-952.74—
2022-03-31—−¥1,081m¥1,166m¥994m—¥-974.48—

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %——
Ordinary margin——
Equity ratio, %85.495.3
Revenue growth——
Net income growth-0.645410.6
Operating cash flow / assets-0.47230.7
Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 0.2% held by other listed companies.

Via /v1/companies/520A/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-06-24: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-06-26 · 資本金及び資本準備金の額の減少並びに剰余金処分の件 · passed. /v1/companies/520A/voting

Ownership changes

All companies →

Trades by 5% holders

From the 60-day trade tables in 5% reports
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
ニュートン・バイオキャピタル I プリカフ・プリヴェ・ドゥ・ドロワ・ベルジュ (Newton Biocapital I, individual holder2026-01-29 – 2026-01-2900.00pt——

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/520A/trades.

5% filings

Large shareholding reports on 520A
FiledFilerStakeChangeStated purpose
2026-04-01JIC Venture Growth Investments Co., Ltd.11.34%—pure investment
2026-03-31Eight Roads Ventures Japan II LP10.88%—pure investment
2026-03-26Newton Biocapital I, pricaf privee de droit belge6.87%—pure investment

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
— issues
Book value
—
Sold in the year
— — issues
Bought in the year
— — issues
Mutual, both reports
0
Held by listed cos.
1

Held by: KNC Laboratories Co., Ltd. 6568

Purposes, all holdings and mutual flags via /v1/companies/520A/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
JICベンチャー・グロース・ファンド1号投資事業有限責任組合1,859,32510.34%
EIGHT ROADS VENTURES JAPAN II LP1,616,0008.99%
NEWTON BIOCAPITAL I SA. PRICAF PRIVEE DE DROIT BELGE1,225,0006.81%
大原薬品工業株式会社875,0004.87%
UntroD 野村クロスオーバーインパクトファンド投資事業有限責任組合827,2004.60%
スペラファーマ株式会社625,0003.48%
MSIVCグローバルアカデミックシーズ投資事業有限責任組合527,5002.93%
F-PRIME CAPITAL PARTNERS LIFE SCIENCES FUND VI LP485,0002.70%
OUVC1号投資事業有限責任組合462,5002.57%
株式会社SBI証券432,2002.40%

Get this as JSON

GET /v1/companies/520A
GET /v1/companies/520A/financials
GET /v1/companies/520A/details
GET /v1/companies/520A/segments
GET /v1/companies/520A/voting
GET /v1/companies/520A/tender-offers
GET /v1/companies/520A/indicators
GET /v1/companies/520A/earnings-releases
GET /v1/events?ticker=520A
GET /v1/companies/520A/trades         
GET /v1/companies/520A/cross-holdings 
GET /v1/companies/520A/brief

Plans from $9 a month · Documentation